Welcome to our dedicated page for Biofrontera news (Ticker: BFRIW), a resource for investors and traders seeking the latest updates and insights on Biofrontera stock.
Biofrontera Inc. (Nasdaq: BFRI, warrants Nasdaq: BFRIW) generates a steady flow of news centered on its dermatology-focused photodynamic therapy (PDT) business. Company press releases highlight commercial performance for Ameluz® PDT, progress in clinical development, and key corporate and regulatory milestones, offering context for both the underlying common stock and the associated BFRIW warrants.
Recent announcements describe record preliminary quarterly revenues, with management attributing growth to sales execution of Ameluz PDT and pricing changes. Biofrontera also reports on clinical trial milestones, such as database locks for a Phase 3 study in actinic keratosis on the extremities, neck and trunk and a Phase 2 study in moderate to severe acne vulgaris, as well as completion of a Phase 1 pharmacokinetics study in peripheral body areas. These updates are framed as supporting future regulatory submissions and potential label expansions.
News items further cover regulatory and intellectual property developments, including submission of a supplemental New Drug Application for superficial basal cell carcinoma and the completion of transfers of FDA approvals, patents, and trademarks for Ameluz and the RhodoLED lamp series to Biofrontera Inc. Corporate and financing news, such as the restructuring of the relationship with Biofrontera AG, preferred stock financings, and the divestiture of the Xepi antibiotic cream license, also appear in the company’s disclosures.
Visitors to this BFRIW news page can review earnings releases, business updates, clinical and regulatory announcements, and transaction-related press releases that collectively illustrate how Biofrontera is advancing its PDT platform in dermatology. For investors following the BFRIW warrants, these news items provide insight into the operating and strategic developments of the underlying issuer, Biofrontera Inc.
Biofrontera (Nasdaq: BFRI) announces its sponsorship of the Fall Clinical Dermatology Conference from October 20-23 in Las Vegas. As a Gold Industry Sponsor, the company will host an exhibit showcasing its flagship drug, Ameluz, and other products. An Advisory Board meeting will enhance education on photodynamic therapy (PDT) among dermatologists. Four research posters related to Ameluz will be presented, highlighting clinical trials and their findings. CEO Erica Monaco emphasizes the importance of these events in advancing knowledge and product visibility.
Biofrontera Inc. (Nasdaq: BFRI) announced the adoption of a limited duration shareholder rights plan to protect shareholder interests. This plan allows for the distribution of one preferred stock purchase right for each share of common stock to shareholders of record on October 24, 2022. The Board believes the current stock price does not reflect the company’s intrinsic value and aims to safeguard against unsolicited offers. The rights become exercisable upon acquisition of 20% or more of the common stock. The plan will expire on October 13, 2023.
Biofrontera Inc. (NASDAQ: BFRI) announced its participation in Renmark Financial Communications’ live Virtual Non-Deal Roadshow Series. The presentations will occur on October 14 at 10:00 AM EDT and October 18 at 1:00 PM CDT, discussing the latest investor presentation and allowing for a live Q&A session. CEO Erica Monaco stated this is the first of multiple events aimed at engaging investors across the U.S. Registrations are available through the provided links, with replays accessible on the company's investor page.
Biofrontera (Nasdaq: BFRI) reported preliminary unaudited product revenues for Q3 2022 at approximately $4.3 million, consistent with Q3 2021. For the first nine months of 2022, revenues are expected to be around $18.5 million, showing a 24% increase year-over-year. The company aims for at least a 30% revenue increase in 2022. CEO Erica Monaco highlighted ongoing efforts to enhance the adoption of PDT for actinic keratosis treatments, despite Q3 typically being a softer sales quarter. Full financial results will be disclosed in November 2022.
Biofrontera Inc. (Nasdaq: BFRI) has announced that CEO Erica Monaco will present at the Roth Inaugural Healthcare Opportunities Conference on October 6, 2022, at 8:30 a.m. Eastern Time in New York City. The company invites investors attending the conference to schedule one-on-one meetings with management.
Biofrontera specializes in dermatological products, focusing on treatments like photodynamic therapy and topical antibiotics for conditions such as actinic keratoses and impetigo.
Biofrontera (Nasdaq: BFRI) announced that its Ameluz® marketing campaign has received two awards from PM360: “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year.” The awards were presented at the 14th Annual Trailblazer Awards on September 22, 2022. The campaign, titled “Danger Lurks Below the Surface,” aimed to raise awareness of actinic keratoses (AK). CEO Erica Monaco emphasized the campaign's impact on revenue growth and brand awareness in the PDT market. The Ameluz campaign has also earned recognition from other industry awards.
Biofrontera (Nasdaq: BFRI) announced the appointment of Gerard DiGirolamo as National Sales Director, effective September 13, 2022. In this newly created role, DiGirolamo will oversee U.S. sales strategies and recruitment for the company’s dermatological products, including Ameluz® and BF-RhodoLED®.
With over 25 years of experience, he previously served as Vice President of Sales at Verrica Pharmaceuticals. His expertise in dermatology and established industry relationships are expected to enhance Biofrontera's commercial initiatives, including the launch of BF-RhodoLED XL®.
Biofrontera Inc. (Nasdaq: BFRI) announced the USPTO's notice of allowance for patent application No. 12/520,759, related to a novel nanoemulsion formulation. This patent covers compositions improving stability and cell penetration for dermatological treatments, enhancing the efficacy of Ameluz®. The company has also received a special designation for expedited review of a patent on novel photodynamic therapy (PDT) illumination protocols, further reinforcing its market position. This positions Biofrontera to broaden its offerings in dermatological treatments.
Biofrontera Inc. (Nasdaq: BFRI) announced that Leslie Hopkins, Associate Director of Marketing, was named a Trailblazer Brand Champion in Dermatology by PM360. The company’s Ameluz® campaign also earned nominations for “Relaunch/Revitalization of the Year” and “Professional Website/Online Initiative of the Year.” This recognition highlights the innovative marketing efforts led by Hopkins in raising awareness of photodynamic therapy for actinic keratosis. The PM360 awards ceremony will take place on September 22 in New York City.
Biofrontera Inc. (Nasdaq: BFRI) reported Q2 2022 revenues of $4.5 million, down 24% year-over-year, while total revenues for H1 2022 reached $14.2 million, up 34%. The company raised $8.7 million through a private placement and an additional $4.3 million post-quarter from warrant exercises. Operating expenses increased to $10.7 million in Q2, leading to a net loss of $0.9 million. Cash and equivalents stood at $31.9 million as of June 30, 2022. The company maintains its 2022 revenue guidance, projecting at least a 30% increase over 2021.